

# IPPC Meeting October 3, 2019



## STATE OF NEW MEXICO GENERAL SERVICES DEPARTMENT

---

### State Pharmaceuticals Program

# Cost Trends Data

Data	FY18	FY19	Change
Avg. Members	60,345	59,642	-1.2%
Usage %	75.7%	76.3%	0.6%
Member Cost	\$7,701,429	\$6,904,233	-10.4%
Total Plan Cost	\$50,950,887	\$53,253,156	4.5%
Plan Cost PMPM	\$70.36	\$74.41	5.8%
Rebates	\$12,051,493	\$15,180,109	26.0%
Net Plan Cost	\$38,899,395	\$38,073,047	-2.1%
Net Cost PMPM	\$53.72	\$53.20	-1.0%
Rebate %	23.7%	28.5%	4.8%
Generic Fill Rate	88.5%	88.7%	0.2%
Non-Specialty Cost	\$27.00	\$25.79	4.5%
Specialty Cost	\$26.72	\$27.41	2.6%



# Top 5 Drugs

July 2018 through March 2019

## Conditions driving prescription volume and cost

Indication/Condition	Number of Prescriptions	Number of Patients	Plan Cost
Inflammatory Conditions	3,744	549	\$4,890,000
Cancer	1,757	329	\$4,022,000
Multiple Sclerosis	422	57	\$2,288,000
Diabetes	46,003	4,125	\$2,147,000
HIV	837	103	\$1,455,000

## Drugs driving prescriptions volume and cost

Drug	Indication/Condition	Number of Prescriptions	Number of Patients	Plan Cost
Humira Pen	Inflammatory Conditions	339	59	\$1,268,000
Revlimid	Cancer	57	13	\$850,000
Trulicity	Diabetes	1,974	323	\$597,000
Novoeight	Hemophilia	14	2	\$565,000
Enbrel	Inflammatory Conditions	165	30	\$480,000

